JP2009523460A - Ｉｌ−４および／またはｉｌ−１３に結合するリガンド - Google Patents

Ｉｌ−４および／またはｉｌ−１３に結合するリガンド Download PDF

Info

Publication number
JP2009523460A
JP2009523460A JP2008551864A JP2008551864A JP2009523460A JP 2009523460 A JP2009523460 A JP 2009523460A JP 2008551864 A JP2008551864 A JP 2008551864A JP 2008551864 A JP2008551864 A JP 2008551864A JP 2009523460 A JP2009523460 A JP 2009523460A
Authority
JP
Japan
Prior art keywords
seq
dom10
dom9
ligand
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008551864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523460A5 (enExample
Inventor
トムリンソン，イアン
ストゥープ，エイドリアーン，アラート
セップ，アーミン
シルバ，イヌシャ デ
ディメック，キャロライン，ジェイ．
プペッカ，マウゴジャータ
ウィルト，ルドルフ，エム．，ティー． デ
ドリュー，フィリップ，ディー．
ホームズ，スティーブ
Original Assignee
ドマンティス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドマンティス リミテッド filed Critical ドマンティス リミテッド
Publication of JP2009523460A publication Critical patent/JP2009523460A/ja
Publication of JP2009523460A5 publication Critical patent/JP2009523460A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2008551864A 2006-01-24 2007-01-24 Ｉｌ−４および／またはｉｌ−１３に結合するリガンド Pending JP2009523460A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76170806P 2006-01-24 2006-01-24
PCT/GB2007/000228 WO2007085815A2 (en) 2006-01-24 2007-01-24 Ligands that bind il-4 and/or il-13

Publications (2)

Publication Number Publication Date
JP2009523460A true JP2009523460A (ja) 2009-06-25
JP2009523460A5 JP2009523460A5 (enExample) 2009-11-05

Family

ID=38028503

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008551864A Pending JP2009523460A (ja) 2006-01-24 2007-01-24 Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
JP2008551863A Pending JP2009523459A (ja) 2006-01-24 2007-01-24 天然の連結部を含有する融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008551863A Pending JP2009523459A (ja) 2006-01-24 2007-01-24 天然の連結部を含有する融合タンパク質

Country Status (16)

Country Link
US (3) US20110159003A1 (enExample)
EP (1) EP1976882A2 (enExample)
JP (2) JP2009523460A (enExample)
KR (1) KR20080098382A (enExample)
CN (1) CN101578298A (enExample)
AU (1) AU2007209202A1 (enExample)
BR (1) BRPI0710572A2 (enExample)
CA (1) CA2636854A1 (enExample)
CR (1) CR10179A (enExample)
EA (1) EA200801515A1 (enExample)
IL (1) IL192572A0 (enExample)
MA (1) MA30175B1 (enExample)
NO (1) NO20082942L (enExample)
TW (2) TW200804593A (enExample)
WO (1) WO2007085815A2 (enExample)
ZA (1) ZA200806202B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017018117A (ja) * 2016-08-05 2017-01-26 モガム バイオテクノロジー リサーチ インスティチュート 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用
US10078085B2 (en) 2012-08-22 2018-09-18 Mogam Biothechnology Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
JP2024532454A (ja) * 2022-03-03 2024-09-05 ファイザー・インク 多重特異性抗体およびその使用
JP2025036273A (ja) * 2023-08-30 2025-03-14 ファイザー・インク 多重特異性抗体およびその使用
JP2025036274A (ja) * 2023-08-30 2025-03-14 ファイザー・インク 多重特異性抗体およびその使用

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
WO2009138413A1 (en) * 2008-05-15 2009-11-19 Domantis Limited Single domain antibodies that bind il-13
WO2007134050A2 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2009030285A1 (en) * 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AU2017201007B2 (en) * 2007-10-15 2018-12-13 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
CA2707986A1 (en) * 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
EP2238165B1 (en) * 2008-01-07 2017-07-05 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anti-hiv domain antibodies and method of making and using same
RU2607569C2 (ru) * 2008-03-31 2017-01-10 Дженентек, Инк. Композиции и способы для лечения и диагностики астмы
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
WO2010035012A1 (en) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
AU2009306424A1 (en) * 2008-10-21 2010-04-29 Domantis Limited Ligands that have binding specificity for DC-SIGN
CN102307896B (zh) 2008-10-31 2016-10-12 森托科尔奥索生物科技公司 基于iii型纤连蛋白结构域的支架组合物、方法及用途
EP2358754A1 (en) * 2008-11-26 2011-08-24 Glaxo Group Limited Ligands that bind il-13
CN102307902B (zh) 2008-12-10 2016-02-24 埃博灵克斯股份有限公司 用于治疗与血管发生相关的疾病和病症的针对血管生成素/Tie系统的氨基酸序列和包括其的多肽
EP2435482B1 (en) * 2009-05-28 2019-04-03 Glaxo Group Limited Antigen-binding proteins
EA201190275A1 (ru) * 2009-05-28 2012-11-30 Глаксо Груп Лимитед Белок, связывающий интерлейкин-13 (il-13)
BR112012001681A2 (pt) * 2009-07-16 2019-09-24 Graxo Group Ltd domínios variáveis de ligação de anti-albumina sérica aperfeiçoados
AU2010277629B2 (en) 2009-07-29 2016-05-19 Glaxo Group Limited Anti - TGF - beta receptor type II single domain antibodies
WO2011095545A1 (en) 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
HRP20191071T1 (hr) 2010-02-11 2019-09-20 Ablynx N.V. Postupci i pripravci za pripremu aerosola
HUE029622T2 (en) 2010-04-30 2017-03-28 Janssen Biotech Inc Stabilized fibronectin domain compositions, methods and uses
MX2013007936A (es) 2011-01-06 2013-08-09 Glaxo Group Ltd Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta.
EP2686014A1 (en) 2011-03-16 2014-01-22 Sanofi Uses of a dual v region antibody-like protein
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US9475879B2 (en) 2011-04-21 2016-10-25 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
EP2761066B1 (en) 2011-09-27 2018-12-05 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
US10481164B2 (en) * 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
CA2876904C (en) * 2012-06-22 2019-12-03 Cytomx Therapeutics, Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
HUE064945T2 (hu) 2012-08-21 2024-04-28 Sanofi Biotechnology Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával
US11066467B2 (en) 2013-12-17 2021-07-20 Mhs Care-Innovation Llc Compositions and methods for treating ischemic heart disease
CA2934004C (en) * 2013-12-17 2023-07-04 The Metrohealth System Compositions and methods for treating fatty tissue buildup
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
CN106536754B (zh) 2014-04-11 2021-04-16 诺华股份有限公司 用il-13拮抗剂选择性治疗哮喘的方法
SI3204095T1 (sl) 2014-10-10 2019-08-30 Ablynx N.V. Inhalacijska naprava za uporabo pri zdravljenju bolezni dihal z aerosolom
RU2017115670A (ru) 2014-10-10 2018-11-15 Аблинкс Н.В. Лечение инфекции рсв
EP3218412A1 (en) 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
JP6862343B2 (ja) 2014-12-19 2021-04-21 アブリンクス エン．ヴェー． システイン結合ナノボディダイマー
WO2017191108A1 (en) 2016-05-02 2017-11-09 Ablynx Nv Treatment of rsv infection
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
JP7104703B2 (ja) 2016-12-14 2022-07-21 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
HUE064655T2 (hu) 2017-10-30 2024-04-28 Sanofi Biotechnology IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
CN108855003B (zh) * 2018-06-28 2021-01-05 南开大学 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法
CN111518211B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
JP2022541697A (ja) 2019-02-27 2022-09-27 ジャージャン ナノマブ テクノロジー センター カンパニー リミテッド 高解像度で広範なエピトープを網羅するために、ラクダ科動物抗体を生成する配列ベースのハイスループット法
MX2022000649A (es) 2019-07-16 2022-06-08 Sanofi Biotechnology Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r.
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
US20230279115A1 (en) 2020-04-22 2023-09-07 Mabwell (shanghai) Bioscience Co., Ltd. Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
EP4146704A4 (en) * 2020-05-06 2024-08-28 Dragonfly Therapeutics, Inc. ANTIBODIES DIRECTED AGAINST CLEC12A AND USE THEREOF
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
WO2024038112A1 (en) * 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Improved anti-albumin nanobodies and their uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770403A (en) * 1992-02-19 1998-06-23 Schering Corporation Cloning and exprssion of humanized monoclonal antibodies against human interluekin-4
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
WO2004058821A2 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2005062967A2 (en) * 2003-12-23 2005-07-14 Tanox, Inc. Novel anti-il 13 antibodies and uses thereof
WO2006003407A2 (en) * 2004-07-01 2006-01-12 Glaxo Group Limited Chimeric and humanised monoclonal antibodies against inteleukin- 13

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
CA2554596A1 (en) * 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypetides and therapeutic uses thereof
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770403A (en) * 1992-02-19 1998-06-23 Schering Corporation Cloning and exprssion of humanized monoclonal antibodies against human interluekin-4
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
WO2004058821A2 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2005062967A2 (en) * 2003-12-23 2005-07-14 Tanox, Inc. Novel anti-il 13 antibodies and uses thereof
WO2006003407A2 (en) * 2004-07-01 2006-01-12 Glaxo Group Limited Chimeric and humanised monoclonal antibodies against inteleukin- 13

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5008024025; 'ＤＯＭＡＮＴＩＳ'　ＤＵＡＬ　ＴＡＲＧＥＴＩＮＧ　ＤＯＭＡＩＮ　ＡＮＴＩＢＯＤＩＥＳ　ＳＨＯＷＮ　ＴＯ　ＫＩＬＬ　ＭＵＬＴＩＰＬＥ　ＭＹＥＬＯＭＡ　ＣＥＬＬＳ　ＡＮＤ　ＳＰＡＲＥ　ＨＥＡＬＴＨＹ　ＣＥ' ［ＯＮＬＩＮＥ］ , 20051207, ＤＯＭＡＮＴＩＳ *
JPN5008024026; 'ＦＡＣＴ　ＳＨＥＥＴ-ＣＯＭＰＡＮＹ　ＯＶＥＲＶＩＥＷ' ［ＯＮＬＩＮＥ］ , 20050827, ＤＯＭＡＮＴＩＳ *
JPN5008024027; ＨＯＬＴ，　Ｌ．Ｊ．　ｅｔ　ａｌ．: ＴＲＥＮＤＳ　ＩＮ　ＢＩＯＴＥＣＨＮＯＬＯＧＹ Ｖｏｌ．２１，　Ｎｏ．１１, 200311, Ｐ．４８４-４９０, ＥＬＳＥＶＩＥＲ　ＰＵＢＬＩＣＡＴＩＯＮＳ *
JPN5008024028; ＨＡＲＴ，　Ｔ．Ｋ．　ｅｔ　ａｌ．: ＣＬＩＮＩＣＡＬ　ＡＮＤ　ＥＸＰＥＲＩＭＥＮＴＡＬ　ＩＭＭＵＮＯＬＯＧＹ Ｖｏｌ．１３０，　Ｎｏ．１, 200210, Ｐ．９３-１００ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10078085B2 (en) 2012-08-22 2018-09-18 Mogam Biothechnology Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
JP2017018117A (ja) * 2016-08-05 2017-01-26 モガム バイオテクノロジー リサーチ インスティチュート 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用
JP2024532454A (ja) * 2022-03-03 2024-09-05 ファイザー・インク 多重特異性抗体およびその使用
JP2024532455A (ja) * 2022-03-03 2024-09-05 ファイザー・インク 多重特異性抗体およびその使用
JP7654346B2 (ja) 2022-03-03 2025-04-01 ファイザー・インク 多重特異性抗体およびその使用
JP7665098B2 (ja) 2022-03-03 2025-04-18 ファイザー・インク 多重特異性抗体およびその使用
JP2025036273A (ja) * 2023-08-30 2025-03-14 ファイザー・インク 多重特異性抗体およびその使用
JP2025036274A (ja) * 2023-08-30 2025-03-14 ファイザー・インク 多重特異性抗体およびその使用
JP7668943B2 (ja) 2023-08-30 2025-04-25 ファイザー・インク 多重特異性抗体およびその使用

Also Published As

Publication number Publication date
MA30175B1 (fr) 2009-01-02
BRPI0710572A2 (pt) 2013-01-08
AU2007209202A1 (en) 2007-08-02
TW200740843A (en) 2007-11-01
CN101578298A (zh) 2009-11-11
JP2009523459A (ja) 2009-06-25
CR10179A (es) 2008-10-29
EA200801515A1 (ru) 2009-02-27
ZA200806202B (en) 2009-11-25
NO20082942L (no) 2008-10-15
EP1976882A2 (en) 2008-10-08
CA2636854A1 (en) 2007-08-02
KR20080098382A (ko) 2008-11-07
WO2007085815A3 (en) 2007-11-15
US20090060916A1 (en) 2009-03-05
IL192572A0 (en) 2009-02-11
TW200804593A (en) 2008-01-16
WO2007085815A8 (en) 2008-07-31
US20120093830A1 (en) 2012-04-19
US20110159003A1 (en) 2011-06-30
WO2007085815A2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
JP2009523460A (ja) Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
US7696320B2 (en) Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20130041136A1 (en) Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
US20100021473A1 (en) Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
JP2009517069A (ja) インターロイキン１受容体１型に結合する競合ドメイン抗体フォーマット
JP2009519011A (ja) インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
US20080241166A1 (en) Ligands that bind a receptor
CN102686239B (zh) 稳定的抗-tnfr1多肽、抗体可变结构域和拮抗剂
JP2012509658A (ja) Ｉｌ−１３に結合するリガンド
MX2007006602A (es) Peptidos de dominio plad con vida media en suero aumentada debido a conjugacion con anticuerpos de dominio.
MX2008009528A (en) Ligands that bind il-4 and/or il-13
KR20050024397A (ko) 리간드
MX2008006882A (en) Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
MX2008007369A (en) Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
MX2008007351A (en) Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
MX2008008854A (en) Ligands that have binding specificity for vegf and/or egfr and methods of use therefor
HK1103238A (en) Compositions and methods for treating inflammatory disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120925